Zusammenfassung
Durch den Einsatz potenter Immunsuppressiva steigen die Raten erfolgreicher Organtransplantationen, allerdings auch die Infektionsrisiken. Die Pathogene können aus der Prätransplantationszeit mitgebracht (endogene Reaktivierung), durch das Spenderorgan übertragen oder neu erworben sein. Unter Immunsuppression kann sowohl eine milde klinische Symptomatik als auch eine atypische Laborkonstellation Infekte maskieren. Wichtig ist es, frühzeitig eine gezielte Diagnostik einzuleiten und an seltene Erreger zu denken, die mit mikrobiologischen Standardverfahren oft nicht erfasst werden.
Abstract
Potent immunosuppressive therapies increased the rate of successful solid organ transplantations, but are also associated with augmented risk for infections. The pathogens can originate from the pretransplant period (endogenous reactivation), donor-derived, or newly acquired. Immunosuppression can disguise infection by mild clinical symptoms and atypical laboratory constellation. Therefore, it is important to consider early in the process a systematic diagnostic workflow including rare pathogens which are sometimes not detectable by routine methods.
Literatur
Bodro M, Sabé N, Santín M et al (2012) Clinical features and outcomes of tuberculosis in solid organ transplant recipients. Transplant Proc 44(9):2686–2689
Boutros M, Al-Shaibi M, Chan G, Cantarovich M et al (2012) Clostridium difficile colitis: Increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation 93(10):1051–1057
Bouza E, Loeches B, Munoz P (2007) Fever of unknown origin in solid organ transplant recipients. Infect Dis Clin North Am 21(4):1033–1054 (ix–x)
Clark NM (2009) Nocardia in solid organ transplant recipients. Am J Transplant 9(Suppl 4):S70–S77
van Delden C, Blumberg EA (2009) Multidrug resistant gram-negative bacteria in solid organ transplant recipient. Am J Transplant 9(Suppl 4):S27–S34
Green M, Michaels MG (2013) Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant 13(Suppl 3):41–54
Fischer SA, Avery RK (2009) Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 9(Suppl 4):S7–S18
Fishman JA (2007) Infection in solid-organ transplant recipients. N Engl J Med 357(25):2601–2614
Garzoni C (2009) Multiply resistant gram-positive bacteria methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus (MRSA, VISA, VRSA) in solid organ transplant recipients. Am J Transplant 9(Suppl 4):S41–S49
Hammer S, Meisnera F, Beiras F, Meiser B et al (1998) Procalcitonin: A new marker for the diagnosis of organ rejection and bacterial infections in patients receiving heart and lung transplants. Transpl Immunol 6(4):235–241
Ison MG (2013) Influenza prevention and treatment in transplant recipients and immunocompromised hosts. Influenza Other Respir Viruses 7(Suppl 3):60–66
Jessup M, Brozena SC (2007) State-of-the-art strategies for immunosuppression. Curr Opin Organ Transplant 12(5):536–542
Kotton CN, Kumar D, Caliendo AM et al (2013) Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96(4):333–360
Morales JM, Bloom R, Roth D (2012) Kidney transplantation in patients with hepatitis C virus infection. Contrib Nephrol 176:77–86
Muoz P (2009) Multiply resistant gram-positive bacteria: Vancomycin-resistant enterococcus in solid organ transplant recipients. Am J Transplant 9(Suppl):S50–S56
Pappas PG, Silveira FP (2009) Candida in solid organ transplant recipients. Am J Transplant 9(Suppl 4):S173–S179
Pergam SA, Limaye AP (2009) Varicella zoster virus (VZV) in solid organ transplant recipients. Am J Transplant 9(Suppl 4):S108–S115
Radack KP, Alexander BD (2009) Prophylaxis of invasive mycoses in solid organ transplantation. Curr Infect Dis Rep 11(6):427–434
Razonable RR (2013) Human herpesviruses 6, 7 and 8 in solid organ transplant recipients. Am J Transplant 13(Suppl 3):67–77
Sawyer RG, Crabtree TD, Gleason TG, Antevil JL et al (1999) Impact of solid organ transplantation and immunosuppression on fever, leukocytosis, and physiologic response during bacterial and fungal infections. Clin Transplant 13(3):260–265
Vats A, Randhawa PS, Shapiro R (2006) Diagnosis and treatment of BK virus-associated transplant nephropathy. Adv Exp Med Biol 577:213–227
Witzke O, Hauser IA, Bartels M, Wolf G et al (2012) Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1‑year results of a randomized clinical trial. Transplantation 93:61–68
Zuckerman R, Wald A (2009) Herpes simplex virus infections in solid organ transplant recipients. Am J Transplant 9(Suppl 4):S104–S107
Danksagung
Die Autoren danken Herrn PD Dr. med. Peter Hunold, Klinik für Radiologie und Nuklearmedizin und Frau Dr. med. Christiane Kümpers, Institut für Pathologie, UKSH, Campus Lübeck, für die freundliche Zur Verfügung Stellung der Abbildungen.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
F. Cakiroglu, J. Rupp und M. Nitschke geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Additional information
Redaktion
C. Dodt, München
C. Wrede, Berlin
Rights and permissions
About this article
Cite this article
Cakiroglu, F., Rupp, J. & Nitschke, M. Infektionen nach Organtransplantation. Notfall Rettungsmed 20, 199–205 (2017). https://doi.org/10.1007/s10049-016-0241-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10049-016-0241-y
Schlüsselwörter
- Prätransplantationszeit
- Opportunistische Infektion
- Spenderassoziierte Infektion
- Virale Reaktivierung
- Immunsuppression